文献速递癫痫认知障碍与痴呆

癫痫女性子代的行为结局与神经发育障碍

Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With Epilepsy.
PubMed 文献 · JAMA Neurol · 2024-01-01

MONEAD前瞻性观察队列纳入20个美国癫痫中心的456名妊娠女性,比较癫痫女性子代与非癫痫女性子代在4.5岁时的适应行为,发现两组总体适应功能无显著差异,但宫内抗癫痫发作药物血药浓度越高子代功能越低,推荐对癫痫女性及其子代酌情进行精神心理筛查和转诊。

要点

  • 癫痫女性子代与非癫痫女性子代4.5岁时ABAS-3 GAC评分无显著差异(PE 0.4,95%CI -2.5至3.4,P=.77)。
  • 第三孕期抗癫痫发作药物最大血药浓度越高,子代适应功能越低(PE -7.8,95%CI -12.6至-3.1,P=.001)。
  • 左乙拉西坦(PE -18.9,95%CI -26.8至-10.9,P<.001)与拉莫三嗪(PE -12.0,95%CI -23.7至-0.3,P=.04)呈暴露依赖性关联。

核心结论

  • 服用常用抗癫痫发作药物的癫痫女性子代适应功能与非癫痫女性子代无显著差异,但药物暴露与子代功能存在暴露依赖性关联。
  • 推荐对癫痫女性及其子代酌情进行精神心理筛查和转诊,需进一步研究确认这些发现。

研究设计与样本

  • MONEAD研究为前瞻性观察性队列研究,在美国20个癫痫中心开展。
  • 2012年12月19日至2016年1月13日共纳入456名妊娠癫痫或非癫痫女性,子代在2、3、4.5和6岁时接受正式评估。
  • 统计分析于2022年8月至2023年5月进行。
  • 主要分析纳入302名癫痫女性子代(男143名,47.4%)和84名非癫痫女性子代(男45名,53.6%)。

主要发现

  • 4.5岁时ABAS-3 GAC评分在癫痫女性子代与非癫痫女性子代间无显著差异(PE 0.4,95%CI -2.5至3.4,P=.77)。
  • 校正分析中,第三孕期抗癫痫发作药物最大血药浓度越高,子代功能越低(PE -7.8,95%CI -12.6至-3.1,P=.001)。
  • 左乙拉西坦暴露与子代功能降低相关(PE -18.9,95%CI -26.8至-10.9,P<.001)。
  • 拉莫三嗪暴露与子代功能降低相关(PE -12.0,95%CI -23.7至-0.3,P=.04)。
  • 以第三孕期最大日剂量分析结果类似。

关键数值与推荐

  • 主要结局为4.5岁时ABAS-3 GAC评分。
  • 癫痫女性子代与非癫痫女性子代GAC评分比较:PE 0.4(95%CI -2.5至3.4),P=.77。
  • 第三孕期最大抗癫痫发作药物血药浓度与GAC评分关联:PE -7.8(95%CI -12.6至-3.1),P=.001。
  • 左乙拉西坦:PE -18.9(95%CI -26.8至-10.9),P<.001;拉莫三嗪:PE -12.0(95%CI -23.7至-0.3),P=.04。

临床怎么用

  • 作者建议对癫痫女性及其子代酌情进行精神心理筛查和转诊。
  • 作者指出需进一步研究确认这些发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association of fetal exposure to antiseizure medications (ASMs) with outcomes in childhood are not well delineated. OBJECTIVE: To examine the association of fetal ASM exposure with subsequent adaptive, behavioral or emotional, and neurodevelopmental disorder outcomes at 2, 3, and 4.5 years of age. DESIGN, SETTING, AND PARTICIPANTS: The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is a prospective, observational cohort study conducted at 20 epilepsy centers in the US. A total of 456 pregnant women with epilepsy or without epilepsy were enrolled from December 19, 2012, to January 13, 2016. Children of enrolled women were followed up with formal assessments at 2, 3, 4.5, and 6 years of age. Statistical analysis took place from August 2022 to May 2023. EXPOSURES: Exposures included mother's epilepsy status as well as mother's ASM blood concentration in the third trimester (for children of women with epilepsy). Women with epilepsy were enrolled regardless of ASM regimen. MAIN OUTCOMES AND MEASURES: The primary outcome was the Adaptive Behavior Assessment System, Third Edition (ABAS-3) General Adaptive Composite (GAC) score among children at 4.5 years of age. Children of women with epilepsy and children of women without epilepsy were compared, and the associations of ASM exposures with outcomes among exposed children were assessed. Secondary outcomes involved similar analyses of other related measures. RESULTS: Primary analysis included 302 children of women with epilepsy (143 boys [47.4%]) and 84 children of women without epilepsy (45 boys [53.6%]). Overall adaptive functioning (ABAS-3 GAC score at 4.5 years) did not significantly differ between children of women with epilepsy and children of women without epilepsy (parameter estimate [PE], 0.4 [95% CI, -2.5 to 3.4]; P = .77). However, in adjusted analyses, a significant decrease in functioning was seen with increasing third-trimester maximum ASM blood concentrations (PE, -7.8 [95% CI, -12.6 to -3.1]; P = .001). This decrease in functioning was evident for levetiracetam (PE, -18.9 [95% CI, -26.8 to -10.9]; P < .001) and lamotrigine (PE, -12.0 [95% CI, -23.7 to -0.3]; P = .04), the ASMs with sample sizes large enough for analysis. Results were similar with third-trimester maximum daily dose. CONCLUSIONS AND RELEVANCE: This study suggests that adaptive functioning of children of women with epilepsy taking commonly used ASMs did not significantly differ from that of children of women without epilepsy, but there was an exposure-dependent association of ASMs with functioning. Thus, psychiatric or psychological screening and referral of women with epilepsy and their offspring are recommended when appropriate. Additional research is needed to confirm these findings.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cohen MJ, Meador KJ, Loring DW, et al. Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With Epilepsy. JAMA Neurol. 2024. PMID: 37983058. doi:10.1001/jamaneurol.2023.4315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。